Joël Ménard

Q: What Schools Are Affiliated With Joël Ménard

Joël Ménard is affiliated with the following schools: Paris Diderot University, Sorbonne University, Humboldt University of Berlin, Université Paris Cité

Joël Ménard's AcademicInfluence.com Rankings

Joël Ménard

Philosophy

#5337

World Rank

#8105

Historical Rank

Logic

#2631

World Rank

#3647

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Joël Ménard's Degrees

Doctorate Medicine Université Paris Cité

Why Is Joël Ménard Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Joël Ménard's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial (1998) (5865)
Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. (2004) (664)
Clearance systems in the brain—implications for Alzheimer disease (2015) (632)
Measurement of renin activity, concentration and substrate in rat plasma by radioimmunoassay of angiotensin I. (1972) (484)
Clearance systems in the brain-implications for Alzheimer disease. (2015) (434)
1993 Guidelines for the Management of Mild Hypertension: Memorandum From a World Health Organization/ International Society of Hypertension Meeting (1993) (348)
Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. (1996) (328)
Masked hypertension: a systematic review. (2008) (297)
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) (2004) (285)
Efficacy and tolerance of spironolactone in essential hypertension. (1987) (256)
Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. (2004) (234)
Determinants of angiotensin II generation during converting enzyme inhibition. (1990) (232)
Antiandrogenic effect of spirolactones: mechanism of action. (1975) (227)
Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. (1995) (224)
Serial left ventricular adaptations in world-class professional cyclists: implications for disease screening and follow-up. (2004) (212)
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism (2011) (203)
The number needed to treat: a clinically useful nomogram in its proper context (1996) (200)
Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists (2004) (197)
Cardiac weight in hypertension induced by nitric oxide synthase blockade. (1993) (191)
Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. (1996) (177)
A micromethod for measurement of renin in the plasma and kidney of rats. (1967) (174)
Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial (2011) (174)
Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement. (2009) (172)
The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. (1993) (165)
Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice (2001) (160)
Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. (1995) (160)
Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats (2005) (158)
1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. (1993) (152)
Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. (1997) (146)
High human renin hypertension in transgenic rats. (1997) (146)
Additive effects of losartan and enalapril on blood pressure and plasma active renin. (1997) (143)
Aldosterone Synthase Inhibition With LCI699: A Proof-of-Concept Study in Patients With Primary Aldosteronism (2010) (141)
Systemic hypertension after cardiac transplantation: effect of cyclosporine on the renin-angiotensin-aldosterone system. (1985) (139)
Sequential nephron blockade versus sequential renin–angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study (2012) (136)
New monoclonal antibodies directed against human renin. Powerful tools for the investigation of the renin system. (1984) (131)
Identity of angiotensinogen precursors of rat brain and liver (1984) (127)
Home self blood pressure measurement in general practice. The SMART study. Self-measurement for the Assessment of the Response to Trandolapril. (1996) (123)
Local angiotensin II generation in the rat heart: role of renin uptake. (1998) (123)
Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. (1990) (120)
Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994. (1998) (119)
Multiple forms of human renin. Purification and characterization. (1979) (118)
High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. (1997) (111)
Direct immunometric assay of active renin in human plasma. (1985) (109)
Vascular angiotensin-converting enzyme expression regulates local angiotensin II. (1997) (109)
Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. (1994) (98)
Renin biosynthesis by human tumoral juxtaglomerular cells. Evidences for a renin precursor. (1984) (98)
Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding (1997) (98)
Measurement of urinary kallikrein activity. Species differences in kinin production. (1981) (97)
Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. Subcommittee of WHO/ISH Mild Hypertension Liaison committee. (1993) (95)
The 45-year story of the development of an anti-aldosterone more specific than spironolactone (2004) (95)
M235T variant of the human angiotensinogen gene in unselected hypertensive patients (1993) (94)
Influence of obesity on the diagnostic value of electrocardiographic criteria for detecting left ventricular hypertrophy. (1996) (93)
Human chorionic cells in primary culture: a model for renin biosynthesis. (1982) (89)
Rat angiotensinogen and des(angiotensin I)angiotensinogen: purification, characterization, and partial sequencing. (1981) (88)
Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal humans. Studies using a direct immunoradiometric assay. (1989) (87)
Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. (2007) (87)
Nonproportional changes in plasma renin concentration, renal renin content, and rat renin messenger RNA. (1985) (87)
Pilot study of combined blockade of the renin–angiotensin system in essential hypertensive patients (2000) (86)
Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk (2002) (85)
Antialdosterones: incidence and prevention of sexual side effects. (1989) (85)
Effects of antihypertensive treatment in one-clip, two kidney hypertension in rats. (1986) (83)
Angiotensin I converting enzyme in human intestine and kidney (2004) (83)
Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. (1989) (81)
Self‐measurement of blood pressure at home to evaluate drug effects by the trough: peak ratio (1994) (81)
Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. (1994) (81)
Binding of glycyrrhetinic acid to kidney mineralocorticoid and glucocorticoid receptors. (1975) (81)
Factors predictive of attendance at clinic and blood pressure control in hypertensive patients. (1983) (79)
Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study (2001) (78)
Aldosterone synthase inhibition in humans. (2013) (76)
Biochemical tests for diagnosis of phaeochromocytoma: urinary versus plasma determinations. (1981) (72)
Crossover design to test antihypertensive drugs with self-recorded blood pressure. (1988) (72)
Which Definition for Echocardiographic Left Ventricular Hypertrophy? (1995) (70)
Feasibility study of N-of-1 trials with blood pressure self-monitoring in hypertension. (1995) (69)
20-Year prevalence projections for dementia and impact of preventive policy about risk factors (2013) (68)
Use of a specific antiserum for renin detection in human kidney. (1980) (67)
Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. (1989) (66)
Active immunization against renin in normotensive marmoset. (1987) (66)
Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. (1990) (66)
Direct radioimmunoassay of human renin. (1979) (64)
Comparative enzymatic studies of human renin acting on pure natural or synthetic substrates. (1987) (64)
Decreased renin release and constant kallikrein secretion after injection of L-NAME in isolated perfused rat kidney. (1992) (64)
Immunologic identification of both plasma and human renal inactive renin as prorenin. (1985) (63)
Dietary sources and correlates of sodium and potassium intakes in the French general population (2009) (63)
Renin-secreting tumors. (1994) (63)
Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. (2011) (61)
[Screening for phaeochromocytoma : in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma (author's transl)]. (1981) (60)
Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. (2007) (60)
Biochemistry and regulation of angiotensinogen. (1983) (60)
Benefits of a computer-assisted education program for hypertensive patients compared with standard education tools. (1994) (58)
Investigation of aldosterone-synthase inhibition in rats (2006) (58)
Pepstatin, an inhibitor for renin purification by affinity chromatography (1973) (56)
High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations (2008) (56)
Angiotensinogen: an attractive and underrated participant in hypertension and inflammation. (1991) (56)
Immunocytochemical localization of angiotensinogen in rat liver and kidney (2004) (55)
Presence of renin, angiotensinogen, and converting enzyme in human pituitary lactotroph cells and prolactin adenomas. (1986) (55)
Inhibition of human renin by synthetic peptides derived from its prosegment. (1985) (55)
Characterization of plasma and cerebrospinal fluid human angiotensinogen and des-angiotensin I-angiotensinogen by direct radioimmunoassay. (1984) (55)
A study of the renin inhibitor H142 in man. (1985) (55)
Direct radioimmunoassay of rat angiotensinogen and its application to rats in various endocrine states. (1982) (55)
Functions of GI-GPx: lessons from selenium-dependent expression and intracellular localization. (2001) (55)
Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. (2007) (54)
Mice chronically fed a westernized experimental diet as a model of obesity, metabolic syndrome and osteoporosis (2006) (53)
Rapid identification of patients with essential hypertension sensitive to acebutolol (a new cardioselective beta-blocker). (1976) (52)
Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats. (1998) (52)
Synthesis and release of immunoreactive angiotensinogen by rat liver slices. (1983) (50)
Need for plasma angiotensin measurements to investigate converting-enzyme inhibition in humans. (1989) (49)
Treatment of mild to moderate hypertension with or without the converting enzyme inhibitor enalapril. Results of a six-month double-blind trial. (1987) (48)
HYPERTENSIVE CRISIS IN PATIENT WITH PHÆOCHROMOCYTOMA GIVEN METOCLOPRAMIDE (1976) (47)
Human renin inhibitor peptides. (1990) (47)
The vasodilatory effect of endogenous nitric oxide is a major counter-regulatory mechanism in the spontaneously hypertensive rat (1993) (47)
Effects of estrogens on renin substrate and uterine weights in rats. (1973) (47)
Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans. (1999) (46)
Renin content in superficial and deep glomeruli of normal and salt-loaded rats. (1974) (46)
The renin-angiotensin system in thyroidectomized rats. (1981) (45)
Angiotensinogen concentrations and renin clearance : implications for blood pressure regulation. (2000) (44)
Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia. (1998) (44)
Diuretic and natriuretic effects of nifedipine on isolated perfused rat kidneys. (1982) (44)
Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine. (1987) (44)
Molecular cloning of genes encoding branched-chain keto acid dehydrogenase of Pseudomonas putida (1987) (44)
Integrating Drug Pharmacokinetics for Phenotyping Individual Renin Response to Angiotensin II Blockade in Humans (2004) (44)
Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6 month double-blind comparison. (1990) (43)
Unemployment is associated with high cardiovascular event rate and increased all-cause mortality in middle-aged socially privileged individuals (2015) (43)
Effect of antihypertensive treatment on the left ventricular isomyosin profile in one-clip, two kidney hypertensive rats. (1986) (42)
Hemodynamic and Biochemical Consequences of Renin Inhibition by Infusion of CGP 38560A in Normal Volunteers (1989) (42)
Vascular and cardiac remodeling in world class professional cyclists. (1998) (42)
Multiple Ascending Dose Study With the New Renin Inhibitor VTP-27999: Nephrocentric Consequences of Too Much Renin Inhibition (2014) (42)
Immunohistochemical characterization of renin-containing cells in the human juxtaglomerular apparatus during embryonal and fetal development. (1981) (42)
The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects. (1992) (42)
Comparison of the hormonal and renal effects of captopril in severe essential and renovascular hypertension. (1982) (42)
Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. (1995) (42)
Pharmacodynamic effects of dual neutral endopeptidase–angiotensin‐converting enzyme inhibition versus angiotensin‐converting enzyme inhibition in humans (1999) (41)
Conformational changes in prorenin during renin inhibition in vitro and in vivo (2006) (41)
Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension. (1978) (41)
Regulation of kallikrein and renin release by the isolated perfused rat kidney. (1983) (41)
Very low oral doses of vitamin B-12 increase serum concentrations in elderly subjects with food-bound vitamin B-12 malabsorption. (2007) (39)
Hypertension management: the computer as a participant. (1980) (39)
Abnormalities of renin-containing cells in human glomerular and vascular renal diseases. (1983) (39)
The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. (2007) (38)
Renal changes on hyperglycemia and angiotensin-converting enzyme in type 1 diabetes. (1999) (38)
Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. (2006) (38)
Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats. (1999) (37)
Human renin-dependent hypertension in rats transgenic for human angiotensinogen. (1996) (37)
Regulation of prorenin secretion in cultured human transfected juxtaglomerular cells. (1987) (37)
Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats. (1999) (36)
Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure. (1996) (36)
[Can echocardiography identify mildly hypertensive patients at high risk, left untreated, based on current guidelines?]. (1998) (36)
Characterization of precursor and secreted forms of rat angiotensinogen. (1984) (35)
Critical assessment of combination therapy development. (1993) (35)
HORMONAL AND ELECTROLYTE RESPONSES TO THE ALDOSTERONE SYNTHASE INHIBITOR LCI699 IN SODIUM DEPLETED HEALTHY SUBJECTS (2010) (34)
Blood pressure effects of renin inhibition by human renin antiserum in normotensive marmosets. (1984) (34)
Angiotensin-converting enzyme inhibitors. (2001) (34)
Antihypertensive effect of enalapril as first-step treatment of mild and moderate uncomplicated essential hypertension. Evaluation by two methods of blood pressure measurement. (1984) (33)
Limiting factors in the control of BP: why is there a gap between theory and practice? (1995) (33)
Increased plasma renin activity induced in rats by physostigmine and effects of alpha- and beta-receptors blocking drugs thereon. (1970) (33)
Short-term effects of withdrawing angiotensin converting enzyme inhibitor therapy on home self-measured blood pressure in hypertensive patients. (1998) (33)
Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism (2013) (33)
Diagnosis and treatment of renin-secreting tumors. Report of three cases. (1984) (32)
Renin storage and cell differentiation in juxtaglomerular cell tumors: an immunohistochemical and ultrastructural study of three cases. (1984) (32)
Dietary sources and correlates of sodium and potassium intakes in the French general population (2010) (32)
Influence of sodium diet on L-NAME effects on renin release and renal vasoconstriction. (1994) (32)
Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects (2014) (32)
Immunocytochemical localization of renin in juxtaglomerular cells. (1985) (32)
Developmental studies demonstrate age-dependent elevation of renin activity in TGR(mRen2)27 rats. (1995) (31)
Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension (2020) (31)
[The variability of blood pressure]. (1983) (31)
The renin-angiotensin system in pregnancy and parturition. (1986) (31)
Effects of Ro 40-5967, a new calcium antagonist, and enalapril on cardiac remodeling in renal hypertensive rats. (1993) (31)
Isolation of renin-producing human cells by transfection with three simian virus 40 mutants. (1985) (30)
Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest? (2013) (30)
Prorenin Contributes to Angiotensin Peptide Formation in Transgenic Rats With Rat Prorenin Expression Targeted to the Liver (2009) (30)
Influence of the M235T polymorphism of human angiotensinogen (AGT) on plasma AGT and renin concentrations after ethinylestradiol administration. (2000) (30)
Effects of estrogen treatment on plasma renin parameters in the rat. (1973) (29)
Mouse and rat plasma renin concentration and gene expression in (mRen2)27 transgenic rats. (1998) (29)
Synthesis of peptides related to the prosegment of mouse submaxillary gland renin precursor: an approach to renin inhibitors. (1984) (29)
Reduction of plasma and urinary vasopressin during treatment of severe hypertension by captopril (1981) (29)
Self blood pressure measurement at home. (1993) (29)
Erratum: Clearance systems in the brain—implications for Alzheimer diseaser (2016) (28)
Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition? (2006) (28)
Assessment of drug efficacy using home self-blood pressure measurement: the SMART study. Self Measurement for the Assessment of the Response to Trandolapril. (1996) (28)
Influence of observer's expectation on the placebo effect in blood pressure trials (1987) (28)
Seven lessons from seven renin secreting tumors. (1988) (28)
Radioimmunoassay of urinary antidiuretic hormone in man: stimulation-suppression tests. (1974) (27)
Calcium Antagonists‐ACE Inhibitors Combination Therapy: Objectives and Methodology of Clinical Development (1993) (26)
Angiotensin I‐Converting Enzyme And Metabolism Of The Haematological Peptide N‐Acetyl‐Seryl‐Aspartyl‐Lysyl‐Proline (2001) (26)
Genome-Wide Meta-Analyses of Plasma Renin Activity and Concentration Reveal Association With the Kininogen 1 and Prekallikrein Genes (2015) (26)
Haemodynamic effects of dual blockade of the renin–angiotensin system in spontaneously hypertensive rats: influence of salt (2004) (26)
Kallikrein along the rabbit microdissected nephron: A micromethod for its measurement (1984) (26)
Use of a standardized personal medical record by patients with hypertension: a randomized controlled prospective trial. (1995) (26)
Production and characterization of human renin antibodies with region-oriented synthetic peptides. (1987) (25)
Recent developments in pheochromocytoma diagnosis and imaging. (1988) (25)
Conjugative mapping of pyruvate, 2-ketoglutarate, and branched-chain keto acid dehydrogenase genes in Pseudomonas putida mutants (1985) (25)
New renin inhibitors homologous with pepstatin. (1981) (25)
Some lessons from systolic hypertension in the elderly program (SHEP). (1992) (24)
Do physicians estimate reliably the cardiovascular risk of hypertensive patients?. (1995) (24)
Methodologic problems in plasma renin activity measurements. (1976) (24)
Fetal growth retardation in gestational hypertension: relationships with blood pressure levels and the time of onset of hypertension. (1983) (24)
Angiotensin I-converting enzyme in amniotic fluid. (1984) (24)
Computer-assisted techniques for evaluation and treatment of hypertensive patients. (1990) (24)
Abnormal regulation of antidiuretic hormone in idiopathic edema. (1979) (23)
Renal excretion capacity in hydrated desert rodents (Jaculus orientalis andJaculus deserti) (2004) (23)
Mild hypertension: the mysterious viability of a faulty concept. (1995) (22)
A Global View of the Relationships between the Main Behavioural and Clinical Cardiovascular Risk Factors in the GAZEL Prospective Cohort (2016) (22)
Aldosterone metabolism in isolated perfused rat kidney. (1978) (22)
Effects of selective and nonselective beta adrenergic agents on renin secretion in isolated perfused rat kidney. (1980) (22)
In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis. (1999) (22)
Hydrolysis of rat high molecular weight kininogen by purified rat urinary kallikrein: identification of bradykinin as the kinin formed. (1986) (22)
Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans (2006) (22)
Renal damage induced in the clipped kidney of one-clip, two-kidney hypertensive rats during normalization of blood pressure by converting enzyme inhibition. (1987) (22)
Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan. (1999) (22)
Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake. (2002) (22)
Evaluation of slow release nicardipine in essential hypertension by casual and ambulatory blood pressure measurements. Effects of acute versus chronic administration. (1987) (21)
The absolute risk as a guide to influence the treatment decision-making process in mild hypertension. (1997) (21)
Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects. (1997) (21)
Characterization of precursor and secreted forms of human angiotensinogen. (1985) (21)
Immunologic approaches to blockade of the renin-angiotensin system: a review. (1989) (21)
Influence of converting enzyme inhibition on the hormonal and renal adaptation to hyper- and hyponatraemic dehydration. (1986) (21)
Effect of bradykinin and kininogens in isolated rat kidney vasoconstricted by angiotensin II. (1990) (20)
Monoiodinated angiotensins: preparation and characterization by polyacrylamide gel electrophoresis and isoelectric focusing. (1973) (20)
Angiotensinogen's role in ANG formation, renin release, and renal hemodynamics in isolated perfused kidney. (1989) (20)
Anthology of the renin-angiotensin system: a one hundred reference approach to angiotensin II antagonists. (1993) (20)
A comparative analysis of four clinical guidelines for hypertension management (2008) (20)
Biochemical and immunological characterization of ectopic tumoral renin. (1982) (20)
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin–angiotensin blockade for left ventricular mass regression in patients with resistant hypertension (2014) (20)
Cost of hypertension treatment and the price of health. (1992) (20)
NMR-based prediction of cardiovascular risk in diabetes (2007) (20)
Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension (2019) (20)
A computer decision aid for medical prevention: a pilot qualitative study of the Personalized Estimate of Risks (EsPeR) system (2003) (19)
Dual renin–angiotensin system blockade restores blood pressure–renin dependency in individuals with low renin concentrations (2003) (19)
Comparison of Increase in the Enalapril Dose and Addition of Hydrochlorothiazide as Second‐Step Treatment of Hypertensive Patients Not Controlled by Enalapril Alone (1989) (19)
Influence of converting-enzyme inhibition on rat des-angiotensin I-angiotensinogen. (1984) (19)
Effects of the blockade of the renin–angiotensin system in cyclosporin-induced hypertension (1993) (19)
Monoclonal antibody against human renin. (1981) (19)
Plasma renin activity in phaeochromocytoma: effects of beta-blockade and converting enzyme inhibition. (1988) (19)
Inhibition of human plasma renin activity by pepstatin. (1976) (19)
Lack of antihypertensive effects of chronic administration of DL-propranolol in Grollman rats. (1973) (18)
Work environment mediates a large part of social inequalities in the incidence of several common cardiovascular risk factors: Findings from the Gazel cohort. (2018) (18)
A vaccine for hypertension (2007) (18)
Angiotensinogen production and consumption in the adrenalectomized rat. (1985) (17)
How much can blood pressure be lowered? (1983) (17)
Renal segmental infarction: a cause of reversible malignant hypertension. (1984) (17)
Effect of acid trypsin and cold treatment and of renin--plasma interaction on the activity of renin secreted by rat kidney. (1979) (17)
Sodium balance and renin regulation in rats: role of intrinsic renal mechanisms. (1980) (17)
Rat high-molecular-weight kininogen: purification, production of antibodies and demonstration of lack of immunoreactive kininogen in a strain of brown Norway rats. (1985) (17)
IX - 1993 Guidelines for management of mild hypertension. Memorandum from a WHO/ISH meeting (1993) (17)
Comparison of the Angiotensin II Antagonist UP269–6 with the Angiotensin Converting Enzyme Inhibitor Enalapril in Normotensive Volunteers Challenged with Angiotensin I (1995) (17)
Partial characterization of hog renin purified by affinity chromatography. (1976) (17)
Vaule of renin measurement, saralasin test, and acebutolol treatment in hypertension. (1979) (17)
Effect of acute potassium loading on plasma renin and on urinary aldosterone in rats. (1977) (16)
Effect of mestranol on cell proliferation and angiotensinogen production in HepG2 cells: relation with the cell cycle and action of tamoxifen. (1987) (16)
The juxtaglomerular apparatus in Bartter's syndrome and related tubulopathies (1988) (16)
Earliest renin containing cell differentiation during ontogenesis in the rat (2004) (16)
Report of the Joint Nomenclature and Standardization Committee of the International Society of Hypertension, American Heart Association and the World Health Organization (1987) (16)
Crossover design for the dose determination of an angiotensin converting enzyme inhibitor in hypertension (1989) (16)
Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum? (2012) (16)
Dose effects of human renin in rats transgenic for human angiotensinogen. (1997) (16)
Fluorimetric assay of renin. (1978) (15)
[Prevalence, treatment and control of hypertension in family practice patients in France during 1994]. (1996) (15)
Abnormalities and drug-induced alterations of vasopressin in human hypertension. (1981) (15)
Direct radioimmunoassay and immunocytochemical localization of renin in human kidneys. (1979) (15)
Measurement of active renin by the 4G1 anti-human renin monoclonal antibody. (1987) (14)
Interactive electronic teaching (ISIS): has the future started? (1996) (14)
Diminished number of renin-containing cells in kidney biopsy samples from hypertensive women immediately postpartum: an immunomorphologic study. (1984) (14)
Long-term experience of spironolactone in essential hypertension. (1988) (14)
Antisera to human renin normalize renin-dependent hypertension in the monkey: therapeutic implications. (1984) (14)
Liver angiotensinogen synthesis and release during captopril treatment in sodium-depleted rats. (1987) (14)
Cost-effectiveness of hypertension treatment. (1996) (14)
Comparison of the Oral Angiotensin II Receptor Antagonist UP 269–6 or Enalapril 20 mg on Blood Pressure and Neurohormonal Effects in Salt‐Deplete Man (1995) (14)
[Detection, diagnosis and localization of pheochromocytoma. 77 cases in a population of 21,420 hypertensive patients]. (1987) (14)
Acute antihypertensive and hormonal effects of a calcium antagonist in essential hypertension. (1982) (14)
Effect of vasodilatators on the structure of the aorta in normotensive ageing rats. (1987) (13)
Effects of calcium blockade on end‐organ damage in experimental hypertension (1997) (13)
Individualization of antihypertensive therapy. (1988) (13)
Osmoregulation and renal effects of vasopressin in normal and mildly hypertensive subjects. (1984) (13)
Selective recognition of M235T angiotensinogen variants and their determination in human plasma by monoclonal antibody-based immunoanalysis. (1996) (13)
Evaluation of the agreement between guidelines and initial antihypertensive drug treatment using a national health care reimbursement database. (2012) (13)
l-Lysine Acts as a Serotonin Type 4 Receptor Antagonist to Counteract In Vitro and In Vivo the Stimulatory Effect of Serotonergic Agents on Aldosterone Secretion in Man (2017) (12)
Doppler-derived pulmonary arterial systolic pressure in patients with known systemic arterial pressures. (1996) (12)
Plasma angiotensin in binephrectomised mice. (1995) (12)
Investigation of the biochemical effects of renin inhibition in normal volunteers treated by an ACE inhibitor. (1992) (12)
Inhibition of renin in the primate Callithrix jacchus (common marmoset). (1983) (12)
Characterization of five epitopes of human renin from a computer model. (1988) (12)
Integrating management and expertise in a computerised system for hypertensive patients. (1987) (12)
Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production (2002) (12)
Physicochemical properties of plasma renin substrate in normal, binephrectomized, and estrogen-treated rats. (1974) (12)
Purification of neurophysins by affinity chromatography. (1974) (12)
Synthesis and Renin Inhibitory Properties of a New Soluble Pepstatin Derivative (1980) (11)
The role of the renin-angiotensin system in blood pressure regulation in normotensive animals and man. (1984) (11)
One-step separation of human plasma angiotensinogen from renin. (1974) (11)
Differential effects of nephrectomy and surgery on plasma kininogens and angiotensinogen in the rat. (1988) (11)
Accuracy and reproducibility of left ventricular mass measurement by subcostal M-mode echocardiography in hypertensive patients and professional bicyclists. (1993) (11)
Role of cyclic AMP in renin secretion by human transfected juxtaglomerular cells. (1986) (11)
Validation of the Test Your Memory (F-TYM Test) in a French Memory Clinic Population (2014) (11)
Monoclonal antibodies to human angiotensinogen: development of an ELISA for measurement of hepatocyte cultured cells content. (1987) (11)
A monoclonal antibody for immunopurification of human renin. (1981) (10)
Copeptin is increased in resistant hypertension (2016) (10)
From the parallel group design to the crossover design, and from the group approach to the individual approach. (1990) (10)
Direct radioimmunoassays of renin and renin substrate during converting-enzyme inhibition. (1982) (10)
Altered Renin Synthesis and Secretion in the Kidneys of Heterozygous Mice with a Null Mutation in the TGF-β2 Gene (2002) (9)
BLOCKADE OF ALDOSTERONE PRODUCTION AS A NOVEL APPROACH TO THE MANAGEMENT OF HIGH BLOOD PRESSURE: EFFICACY AND TOLERABILITY OF THE ALDOSTERONE SYNTHASE INHIBITOR LCI699 IN PATIENTS WITH STAGE 1-2 HYPERTENSION (2010) (9)
Unmasking of the hypotensive effect of nifedipine in normotensives by addition of the angiotensin converting enzyme inhibitor benazepril. (1992) (9)
Effects of Transdermal Clonidine in Young and Elderly Patients with Mild Hypertension: Evaluation by Three Noninvasive Methods of Blood Pressure Measurement (1987) (9)
Effect of Contrasted Sodium Diets on the Pharmacokinetics and Pharmacodynamic Effects of Renin–Angiotensin System Blockers (2013) (9)
Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism (2004) (9)
Structural changes and cyclic GMP content of the aorta after calcium antagonism or angiotensin converting enzyme inhibition in renovascular hypertensive rats (1995) (9)
Continuous versus intermittent angiotensin converting enzyme inhibition in renal hypertensive rats. (1993) (9)
Dose Dependency of Captopril Effects in Severely Hypertensive Patients (1981) (9)
Radioimmunoassay Studies of the Renin-Angiotensin System in Human Hypertension and During Estrogen Treatment (1972) (9)
Can inhibition of the renin-angiotensin system have a cardioprotective effect? (1985) (8)
RENIN INHIBITION: IMMUNOLOGICAL PROCEDURES AND RENIN INHIBITOR PEPTIDES (1988) (8)
Plasma renin substrate sensitivity to oestrogens and oestrogen metabolism in cirrhosis (1978) (8)
Hypertension management: the role of the computer in improving patient compliance. (1982) (8)
ARTEL: An Expert System in Hypertension for the General Practitioner (1988) (8)
Deciphering the Role of Vasopressin in Primary Aldosteronism. (2015) (8)
Do we need angiotensin II antagonists to treat hypertensive patients? (1997) (8)
Health insurance coverage is the single most prominent socioeconomic factor associated with cardiovascular drug delivery in the French population (2012) (8)
Clinical significance of the metabolic effects of antihypertensive drugs. (1993) (8)
Renin localization in segmental renal hypoplasia (1981) (8)
Soluble pepstatins: a new approach to blockade in vivo of the renin-angiotensin system. (1978) (7)
Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease. (2009) (7)
Commentary: Renin assays a debate for clinicians, not only for specialists (1995) (7)
A double-blind randomized evaluation of converting enzyme inhibition as the first-step treatment of mild to moderate hypertension. (1984) (7)
Arterial and Endocrine Effects of a Combination of an Angiotensin Converting Enzyme Inhibitor and a Vasodilator in Normotensive Healthy Volunteers (1991) (7)
Spirolactones: clinical and pharmacologic studies. (1977) (7)
PROGRESS – perindopril protection against recurrent stroke study: status in July 1996 (1996) (7)
[Combined blockade of the renin-angiotensin system]. (1999) (7)
[Primary hyperaldosteronism: diagnostic value of the administration of a single dose of captopril]. (1983) (7)
Primary Cardiovascular Disease Risk Factors Predicted by Poor Working Conditions in the GAZEL Cohort (2017) (7)
[A simple diagnostic test for primary hyperaldosteronism]. (1983) (6)
Clinical and Biochemical Effects of the Renin Inhibitor H142 in Humans (1987) (6)
[Testing an expert system for hypertension]. (1986) (6)
Production and characterization of monoclonal antibodies to rat angiotensinogen. (1984) (6)
[Radioimmunoassays of aldosterone and plasma renin activity. Application to the diagnosis of primary aldosteronism]. (1973) (6)
Use of crossover trials to obtain antihypertensive dose-response curves and to study combination therapy during the development of benazepril. (1990) (6)
[Results of the surgical treatment of Conn's adenomas]. (1987) (6)
Long-term cardiac effects of hypotensive agents in normotensive mature rats: comparison of beta-blocking agent and converting enzyme inhibition. (1989) (6)
Purification of 125I-labelled lysine-vasopressin by affinity chromatography on sepharose-bound neurophysins. (1973) (6)
[Vasodilator effect of nitric oxide is a necessary counter-regulation in the spontaneously hypertensive rat]. (1993) (6)
AMBULATORY BLOOD PRESSURE MONITORING. DISUCSSION (1996) (6)
Vascular effects and metabolism of angiotensins and their metabolites in the isolated perfused rat kidney. (1983) (6)
Teletransmission of home blood pressure monitoring: making it easier. (2008) (6)
Oil and water? Economic advantage and biomedical progress do not mix well in a government guidelines committee. (1994) (6)
Angiotensin I-converting enzyme in foetal membranes and chorionic cells in culture. (1984) (6)
Mouse submaxillary renin: a useful model for the study of renal renin. (1983) (6)
Trough to peak ratio as a guide to BP control: measurement and calculation (1998) (6)
Renin Purification and Cloning (1991) (5)
Masked hypertension : a systematic review. Commentary (2008) (5)
Immunochemical differences between angiotensin I-forming enzymes in man. (1980) (5)
Combining risks estimations and clinical practice guidelines in a computer decision aid: a pilot study of the EsPeR system (2003) (5)
[Evaluation of the quality of filling out medical records in a hypertension consultation]. (1997) (5)
High incidence of hypertension in middle-aged French adults in the late 1990s (2008) (5)
Dynamic study of antidiuretic hormone during benign mineralocorticoid and metacorticoid hypertension. (1980) (5)
Hypertension costs: source, evolution and impact of cost-containment measures in various health-care systems. (1989) (5)
Activation of renin in an anaplastic pulmonary adenocarcinoma. (1981) (5)
Renal arteriovenous fistula: a model for renovascular hypertension in rat. (1983) (5)
Processing of rat and human angiotensinogen precursors by microsomal membranes (1985) (5)
Physicochemical properties of non-activated and activated renin from human amniotic fluid. (1979) (5)
Review: Measurement of plasma renin: a critical review of methodology (2010) (5)
Enzymatic activity of renin in plasma of normal and uraemic subjects. (1984) (5)
[Treatment of arterial hypertension. Comparative effectiveness of the day care hospital and classical hospitalization]. (1983) (5)
[Sexual side-effects of spironolactones. Possible mechanisms of their anti-androgen action]. (1976) (4)
Mouse and rat plasma renin concentration and gene expression in (mRen2)27 transgenic rats. (1998) (4)
Consequences of renal morphologic damage induced by inhibition of converting enzyme in rat renovascular hypertension. (1987) (4)
Gel Electkophoretic Separation of Angiotensins I, II and III (1985) (4)
Influence of furosemide andd-l propranolol on glomerular filtration rate and renin secretion in the rat (1974) (4)
Predictive Factors of the Blood Pressure Fall Induced by Intravenous Nicardipine (1989) (4)
Improving hypertension treatment. Where should we put our efforts: new drugs, new concepts, or new management? (1992) (4)
An attempt to improve blood pressure control in the French population: information and outcome awareness at the general practitioner level. (1998) (4)
[A computerized medical record for the follow-up of hypertensive patients (author's transl)]. (1980) (4)
[Validation of Oscillomat, a device for self-measurement of blood pressure. Comparison with mercury sphygmomanometers]. (1991) (4)
Acute effects of a pseudo-tetrapeptide as renin inhibitor on blood pressure and renin-angiotensin system of sodium-repleted and sodium-depleted hypertensive patients. (1993) (4)
Distinctive unhealthy eating pattern in free-living middle-aged hypertensives when compared with dyslipidemic or overweight patients (2013) (4)
Noradrenaline producing phaeochromocytomas with absent pressor response to beta-blockade. (1979) (4)
Renin Activity and the Response to Beta-Blockade (1981) (4)
[Audit of the treatment of arterial hypertension in specialized consultation]. (1999) (4)
[Evaluation of a computer assisted training program for hypertensive patients]. (1994) (4)
[Antinuclear antibodies and lupus induced during treatment of arterial hypertension. Role of beta-blockers and alpha-methyldopa]. (1983) (4)
Influence of educational and sociocultural factors on hypertension care. (1985) (4)
Efficacy and influence on quality of life of enalapril as a first step treatment of hypertension. (1987) (4)
Integration of trial, meta-analysis and cohort results with treatment guidelines (1996) (4)
[Incidence and fetal impact of hypertension in pregnancy: study of 2996 pregnancies]. (1982) (4)
Effects of glucocorticoids and antiglucocorticoid on angiotensinogen production by hepatoma cells in culture (1984) (4)
Test diagnostique simple de l'hyperaldostéronisme primaire. (1983) (3)
The effects of converting enzyme inhibitors on plasma angiotensinogen and plasma aldosterone in sodium-depleted rats. (1983) (3)
Renin uptake by the right kidney in the rat following partial clamping of the left renal artery (1980) (3)
Compliance to Antihypertensive Therapy (1982) (3)
[Effect of 2 types of diet changes on dietary habits, body weight and cholesterol levels in high risk cardiovascular patients]. (1995) (3)
BLOOD PRESSURE AND POTASSIUM EFFECTS OF THE NEW DIRECT ALDOSTERONE SYNTHASE INHIBITOR, LCI699, IN PATIENTS WITH PRIMARY ALDOSTERONISM: 9D.03 (2010) (3)
[Demonstration of differences in the effect of 2 antihypertensive agents by self blood pressure measurement: comparison of trandolapril and perindopril]. (1997) (3)
[From the renin gene to renin inhibitors]. (1986) (3)
Blood pressure and renin–angiotensin system resetting in transgenic rats with elevated plasma Val5-angiotensinogen (2012) (3)
Human antirenin antibody: a new tool for studying the renin-angiotensin system. (1983) (3)
Clonidine, acebutolol and their interaction in essential hypertension: effects on blood pressure and the control of water and electrolyte balance. (1983) (3)
Introduction à la sémiologie quantitative. (1996) (3)
[Home blood pressure monitoring]. (1998) (2)
[Equilibration of the treatment of severe arterial hypertension. Significance of d-1 propranolol]. (1975) (2)
34Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension (2019) (2)
SUPERIORITY OF LOW DOSE DIURETICS COMBINATION OVER RENIN-ANGIOTENSIN BLOCKERS COMBINATION IN RESISTANT HYPERTENSION: PP.16.89 (2010) (2)
Drug-resistant hypertension. (1990) (2)
Twenty-four hour blood pressure control and trough to peak ratio: who, when, how and why? (1998) (2)
[Measurement of antidiuretic hormone and plasma renin activity in desert rodents]. (1981) (2)
Effects of circulating renin substrate on renal function in isolated perfused rat kidney. (1983) (2)
Direct radioimmunoassay for rat high molecular weight kininogen. Measurement of immunoreactive high molecular weight kininogen in normal and kininogen deficient plasma. (1987) (2)
Renin inhibition: immunological procedures and renin inhibitor peptides. (1989) (2)
[Prevalence of carotid artery stenosis in nonagenarians: Survey in a primary care hospital]. (2017) (2)
[Role of the renin-angiotensin system in arterial hypertension with aortic coarctation in young adults]. (1980) (2)
Acute inhibition of the renin-angiotensin system: interest and limits to detect surgically curable hypertension. (1985) (2)
[Critical evaluation of the functional signs of arterial hypertension]. (1982) (2)
[Variability of arterial pressure during consultation. Effect of the physician and patient characteristics]. (1985) (2)
Renin-angiotensin system blockade: to what extent? (2004) (2)
Angiotensin I-Converting Enzyme Inhibition but Not Angiotensin II Suppression Alters Angiotensin I-Converting Enzyme Gene Expression in Vessels and Epithelia 1 (1998) (2)
[Predictive factors of resistance to antihypertensive treatment]. (1987) (2)
15. Analytical study of gluco- and mineralocorticoid receptors in rat kidney. Dramatic protective effect of ligand on mineralocorticoid receptors (1975) (2)
[Access to medical care of patient with hypertension: influence of socio-professional categories (author's transl)]. (1980) (2)
[Short and long-term clinical tolerance of hypertensive treatment during the HOT study (Hypertension Optimal Treatment)]. (1996) (2)
New strategies in cardiovascular disease management: Summary of round table discussion (1997) (2)
Metabolism of bradykinin in isolated perfused rat kidney. Measurement of kininase activity in perfusate and urine. (1986) (2)
Influence of beta-blockade on aldosterone metabolism under normal and low sodium diet in man. (1977) (2)
A comparison of multiple forms of renin in rat renal perfusate with those in renal extract. (1980) (2)
In vitro biosynthesis of human renin: evidence for a high molecular weight form. (1982) (2)
[Antiandrogenic effect of spirolactones: different mechanisms of action (author's transl)]. (1976) (2)
Potentials and limitations of angiotensin converting enzyme inhibition in the treatment of hypertension. (1984) (2)
NON ANTIHYPERTENSIVE DOSES OF PERINDOPRIL AFFORD RENOPROTECTION IN LYON GENETICALLY HYPERTENSIVE RAT: 6C.5 (2004) (1)
[Double-blind evaluation of slow-release nicardipine using different methods of blood pressure measurement. Predictive value of the acute response to intravenous nicardipine]. (1987) (1)
[A new diagnostic test for primary tumoral hyperaldosteronism]. (1983) (1)
10 Evaluation of a computer‐assisted education program for hypertensive patients (1994) (1)
Can echocardiography identify mildly hypertensive patients at high risk, left untreated based on current guidelines? (1999) (1)
Methodological aspects: general discussion (1996) (1)
Leptin Receptor and Membrane Microviscosity of Erythrocytes in Essential Hypertension (2006) (1)
New Clothes for the Emperor (2002) (1)
IgG versus albumin for measurement of plasma volume in normal and hypertensive men (1978) (1)
[Effects of restriction, depletion and overload of sodium on plasma renin and juxta-glomerular index of the rat]. (1971) (1)
[Cooperative study of systolic arterial hypertension in the elderly patient (SHEP). Comments]. (1992) (1)
MICROALBUMINURIA IN ESSENTIAL HYPERTENSION AND DIABETES MELLITUS. DISCUSSION (1996) (1)
Is Plasma Renin Activity Genetically Determined and How Much Does It Matter for Treating Hypertension? (2018) (1)
G13: Superiority of home blood pressure versus office measurements to test antihypertensive drugs (1997) (1)
[Do WHO-ISH guidelines identify high risk mild hypertensive patients?]. (1998) (1)
Implementation and assessment of an hypertension expert system (1987) (1)
Prevalence, treatment and control of high blood pressure in patients treated by general practitioners in France during 1994 (1997) (1)
Development of a model of human renin-dependent hypertension in rats (1997) (1)
of the Renin System (1984) (1)
[Comparison of the effect of captopril and minoxidil on left ventricular mass. Results of a 6-month comparative double-blind test]. (1987) (1)
Individualization of antihypertensive treatment: Theory and practice (1995) (1)
[Effect of furosemide and ACTH on plasma renin, aldosterone and cortisol levels in normal man]. (1975) (1)
HORMONAL EFFECTS OF THE NEW DIRECT ALDOSTERONE SYNTHASE INHIBITOR, LCI699, IN PATIENTS WITH PRIMARY ALDOSTERONISM: 5C.06 (2010) (1)
The ARTEMIS data and knowledge base for hypertension (1991) (1)
P-354: Eplerenone dose-response relationship for aldosterone blockade (2003) (1)
Friday May 30, Ballroom A, 10:30 am Theme III: Risk vs. Risk Factors as a Guide to Treatment: Blood pressure treatment and cardiovascular risk management are not interchangeable objectives (1997) (1)
Clinical tolerance of short- and long-term antihypertensive treatment during the HOT study (1997) (1)
Evaluation of the capacity of gel electrophoresis, steadystate and transient state electrofocusing to resolve native human des‐angiotensin‐I‐angiotensinogen from angiotensinogen (1985) (1)
EPIDEMIOLOGY OF RENIN (1983) (1)
Plasma Angiotensin I Determines the Rate of Angiotensin II Generation Even during ACE Inhibition (1988) (1)
[Development of a model of human renin hypertension in rats]. (1996) (1)
β-Adrenoceptor Blocking Drugs and the Renin-Angiotensin System (1980) (1)
Critical assessment of international clinical development programmes for new antihypertensive drugs (1993) (1)
REFRACTORY HYPERTENSION: EFFICACY AND SAFETY OF A TRIPLE DIURETIC ASSOCIATION (2004) (1)
The future of hypertension and renin research. (1986) (1)
THE ANTI-INFLAMMATORY OF GLYCYRRHETINIC ACID TO KIDNEY MINERALCORTICOID AND GLUCOCORTICOID RECEPTOR (1975) (1)
[Parotid steroid excretion in relation to plasma cortisol variations]. (1973) (1)
Sandford Lloyd Skinner (1933–2005) (2005) (0)
231. Mineralo-corticoid-like effect of glycyrrhetinic acid (1974) (0)
[Renin system inhibitors at the level of the renin-substrate reaction]. (1983) (0)
[Development and application of the radioimmunologic assay of plasma aldosterone and renin activity]. (1972) (0)
CONFORMATIONAL CHANGES IN PRORENIN DURING RENIN INHIBITION IN VITRO AND IN VIVO AS ASSESSED BY A CHEMOLUMINESCENCE IMMUNOASSAY: PP.24.469 (2010) (0)
[Introduction to quantitative semiology]. (1996) (0)
[Numerical angiography in the evaluation of arterial hypertension]. (1983) (0)
H035 Eplerenone survival benefits in heart failure patients post myocardial infarction are independent from its diuretic and potassium-sparing properties: insight from the ephesus data (2009) (0)
[Interest in multifactorial prevention of coronary disease in hypertensives: use of beta blockaders]. (1979) (0)
Immunodetection of M235T variants of human angiotensinogen (1997) (0)
Is it Possible to Differentiate between Angiotensin II Type 1 (AT1) Receptor Blockers in Normotensive Volunteers? (2000) (0)
[How to advance antihypertensive therapy]. (1974) (0)
[Ambulatory blood pressure monitoring must be utilized more often]. (2003) (0)
[Computerized evaluation of medical care. Example of arterial hypertension]. (1983) (0)
[The decision to treat moderate hypertension: repetition of office visits or ambulatory monitoring of arterial pressure?]. (1987) (0)
NO INFLUENCE OF THE INSERTION/DELETION POLYMORPHISM OF THE ANGIOTENSIN I CONVERTING ENZYME GENE ON N-Acetyl-Ser-Asp-Lys-Pro METABOLISM: P3.234 (2000) (0)
Masked hypertension: a syste matic review (2008) (0)
[Measurement of platelet catecholamine content for the diagnosis of pheochromocytoma with intermittent hypertension]. (1987) (0)
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) (2004) (0)
[Role of vasopressin in arterial hypertension]. (1982) (0)
[Plasma renin and noradrenalin levels during hypotensive therapy using acebutolol (author's transl)]. (1979) (0)
[Kinetic study of the metabolism and urinary excretion of cortisol in the isolated perfused rat kidney (author's transl) (proceedings)]. (1976) (0)
[Immunohistochemical localization of renin in segmental renal hypoplasia]. (1982) (0)
Predictive Factors of the Acute and Chronic Blood Pressure Fall Induced by the Calcium Antagonist Nicardipine (1988) (0)
Les inhibiteurs de l'enzyme de conversion (1984) (0)
Plasma Renin Activity in the Renal Veins of Three Patients with Juxtaglomerular Cell Renin Tumors Treatment Case 1 Sodium depletion + beta-blockers Case 2 Sodium depletion Sodium depletion Captopril Captopril Case 3 Normal sodium intake Captopril Right renal vein (2005) (0)
[Mode of action of mineralocorticoides: their binding with transcortin and cytoselic renal receptors]. (1975) (0)
COST-EFFECTIVENESS CALCULATIONS FROM TRIALS. DISUCUSSION (1996) (0)
[Changes in angiotensinogen and des-angiotensin I-angiotensinogen in man and rat upon inhibition of converting enzyme]. (1982) (0)
[New methods of clinical exploration of aldosterone metabolism]. (1972) (0)
[Effects of ethyl chlorophenoxyisobutyrate on postprandial lipemia]. (1966) (0)
1014-99 The Hypotensive Effect of the Angiotensin II Antagonist EXP 3174 Depends upon the Renin-Angiotensin System Activation in Conscious Dogs with Heart Failure (1995) (0)
New pepstatinderivate and process for their manufacture (1978) (0)
COMPARISON OF BLOOD PRESSURE, POTASSIUM, RENIN AND ALDOSTERONE EFFECTS OF ALDOSTERONE SYNTHASE INHIBITION VS. MINERALOCORTICOID BLOCKADE IN PATIENTS WITH PRIMARY ALDOSTERONISM: 4A.02 (2011) (0)
[Definition and consequences of blocking the renin-angiotensin system by converting enzyme inhibition]. (1987) (0)
APPLICATION OF HUMAN RENIN ANTIBODIES (1983) (0)
[Comparison of the cardiac, renal and endocrine effects of converting enzyme inhibition with those of a classical triple therapy in experimental renal hypertension]. (1984) (0)
77 Oral or vaginal administration of ethinyl estradiol has a similar impact on liver proteins and coagulation markers: results of a randomized, cross-over study (2007) (0)
[The treatment of hypertension: long-term strategy]. (1979) (0)
Diagnosis and Treatment of Renin-Secreting T \ imors Report of Three Cases (2005) (0)
430 Dilated cardiomyopathy patterns in very high level endurance athletes: serial evaluation of 286 professional bicyclists of the “Tour de France” (2003) (0)
[Abnormal secretion of renin: theoretical and practical repercussions on renovascular hypertension]. (1974) (0)
[Arterial hypertension: a specialty of the general practitioner]. (1979) (0)
PREDICTIVE FACTORS OF BLOOD PRESSURE CONTROL IN RESISTANT HYPERTENSION TREATED BY SEQUENTIAL NEPHRON BLOCKADE VS SEQUENTIAL RENIN ANGIOTENSIN SYSTEM BLOCKADE: 9A.04 (2011) (0)
Review: Low-dose diuretics, but not high-dose diuretics and β-blockers, reduce coronary heart disease and total mortality (1997) (0)
[Simultaneous measurement of cardiac output by indium 113 m detected externally and by dye dilution of indocyanine green]. (1977) (0)
Clinical outcomes by atherosclerotic cardiovascular disease risk score and blood pressure level in high risk individuals with type 2 diabetes (2022) (0)
Combined Blockade of the Renin Angiotensin System with ACE Inhibitors and AT1 Receptor Antagonists (2004) (0)
[Effect of furosemide and d-1-propranolol on glomerular filtration and renin secretin in rats]. (1975) (0)
25. Ethinyl estradiol and hydrocortisone effect on cell proliferation and angiotensinogen Fao cells (1982) (0)
From the renin gene to renin inhibitors. (1987) (0)
What Can Be Learnt from the Results of the High Blood Pressure Trials (1985) (0)
[Metabolism of water and sodium during normal pregnancy and pregnancy toxemia]. (1972) (0)
[Proceedings: Role of endogenous and exogenous ACTH on aldosterone secretion (author's transl)]. (1975) (0)
Renin inhibition by synthetic peptides related to mouse and human renin prosegments. (1984) (0)
Angiotensin II antagonism refined : candesartan cilexetil : a novel long-acting selective AT[1] receptor blocker (1997) (0)
[Is it still necessary to look for the surgically-treatable causes of arterial hypertension?]. (1981) (0)
An immunomorphologic study (1984) (0)
[The renin-angiotensin system and its inhibition (author's transl)]. (1981) (0)
[Cardiovascular risk, cholesterol and statins]. (2013) (0)
[Arterial hypertension: risk factor in atheroma]. (1982) (0)
Can echocardiography contribute to therapeutic decision in mild hypertensive patients (1997) (0)
METHODOLOGICAL ASPECTS : GENERAL DISCUSSION. DISCUSSION (1996) (0)
Subject Index Vol. 10, 2002 (2002) (0)
[Effects of minoxidil on blood pressure and plasma volume in refractory hypertension (author's transl)]. (1979) (0)
Proceedings of the joint WHO/ISH symposium on hypertension and cardiovascular disease: Preface (1993) (0)
[Effect of progesterone, and its derivatives, and of progestagens on the metabolism of salt water]. (1979) (0)
PREDICTION OF HUMAN RENIN EPITOPES USING A NEW COMPUTER ALGORITHM (1987) (0)
[Arterial hypertension and social inequalities]. (1979) (0)
CHARACTERISTICS OF CONTROLLED VS. RESISTANT ESSENTIAL HYPERTENSIVE PATIENTS AFTER A STANDARDIZED 4-WEEK THREE DRUG-REGIMEN: PP.43.372 (2011) (0)
New derivatives of pepstatin, their preparation and pharmaceutical compositions containing them (1977) (0)
VIDEO TRAINING FOR BLOOD-PRESSURE SELF-MEASUREMENT: P2.18 (2004) (0)
[Inhibition of the renin-angiotensin system: a major breakthrough in the treatment of arterial hypertension?]. (1980) (0)
New pharmacological approaches in the treatment of mild hypertension. The potential role of converting enzyme inhibitors and calcium blocking agents (1984) (0)
P-228: Pharmacodynamic effects of single oral doses of omapatrilat (40 and 80 mg) and fosinopril (20 mg) during salt depletion and salt repletion in normotensive subjects (2003) (0)
[Comparison of ambulatory blood pressure determinations using the Remler and Spacelabs devices]. (1986) (0)
The History of the Renin–Angiotensin System (2009) (0)
[Micromethod for the determination of plasma renin activity (P.R.A.) in rats and its use in the study of the role of P.R.A]. (1968) (0)
Evaluation of the completion of medical records in a hypertension clinic (1997) (0)
The use of autirenin antibodies to investigate the renin-angiotensin system. (1984) (0)
Human Renal Renin: Purification, Production of Specific Antibodies. Clinical Applications (1980) (0)
[Editorial: Mechanisms of the antihypertensive action of beta-blocking agents]. (1975) (0)
[Decentralization of the ARTEMIS system in a nephrology service in a general hospital]. (1987) (0)
[Alpha-blockers in practice: classification and therapeutic use]. (1981) (0)
[Arterial hypertension in heart transplant patients treated with cyclosporin]. (1985) (0)
[Blood pressure auto-measurement]. (1981) (0)
Hypertension: Scientific, clinical and public perspectives in the 1990's (1995) (0)
Electrophoretic characterization of active renin from human kidney and inactive renin from a human chorionic cell culture (1985) (0)
HOME SELF BLOOD-PRESSURE MEASUREMENT: PATIENT EXPERIENCES (2004) (0)
[Predictability and prevention of hypokalemia induced by hydrochlorothiazide]. (1985) (0)
THE HYPERTENSION TRIALS. DISCUSSION (1996) (0)
Increased dietary NaCl potentiates the effects of elevated prorenin levels on blood pressure and organ disease (2010) (0)
第26回日本腎臓学会総会招請講演I The use of antirenin and antibodies to investigate the renin-angiotensin system (1984) (0)
[Role of scintigraphy in the localization of pheochromocytoma]. (1979) (0)
[With which drug should the general practitioner begin antihypertensive treatment: a diuretic of a beta blocker?]. (1977) (0)
CLINICAL OUTCOMES AND PATIENT CHARACTERISTICS ACCORDING TO THE COMBINATION OF TEN-YEAR RISK OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND SYSTOLIC BLOOD PRESSURE (2021) (0)
ISIS: a computer-assisted education program for hypertensive patients and patients at cardiovascular risk (1994) (0)
[Plasma renin and catecholamine activity in pheochromocytoma]. (1985) (0)
HYPERTENSIVE URGENCIES AFTER AN EMERGENCY CALL FOR A GENERAL PRACTITIONER HOME VISIT (2018) (0)
[Micromethod for the determination of the plasma renin activity (P.R.A.) in the rat and its utilization for the study of the role of P.R.A]. (1968) (0)
Q001: The answer to “What is my BP, doctor?” Depends on whom is asked (1998) (0)
[Is it possible to predict the antihypertensive action of a beta-blocker by an anti-angiotensin?]. (1978) (0)
Counter-regulatory effects of combined ACE-inhibition and calcium antagonism (1988) (0)
[Long term minoxidil therapy in resistant hypertension: effects on blood pressure, on end-organ damage, and side-effects (author's transl)]. (1980) (0)
Contents Vol. 10, 2002 (2002) (0)
[Acebutolol test in moderate arterial hypertension. Action on systolic time intervals]. (1975) (0)
Synthesis ofpeptides related totheprosegment ofmouse submaxillary glandreninprecursor: Anapproach torenininhibitors (aspartyl protease/prorenin/hypertension) (1984) (0)
[Pharmacology of converting enzyme inhibitors (captopril and related products)]. (1982) (0)
[Control of vascular tone by the endothelium: the coupling active vasodilation in the kidney to renin secretion]. (1992) (0)
[The renin-angiotensin-aldosterone system in hypertensive subjects. I-Analytical study of 124 patients (author's transl)]. (1977) (0)
[The renin-angiotensin-aldosterone system in hypertensive subjects. III- The use of beta-blockers in reno-vascular hypertension (author's transl)]. (1977) (0)
[Incidence of beta-blockers on plasma renin activity. Present status]. (1978) (0)
Summary of 1993 WHO/ISH guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Guidelines Sub-Committee of WHO/ISH Mild Hypertension Liaison Committee. (1993) (0)
[Effects of acebutolol on the renin-aldosterone system in essential arterial hypertension]. (1975) (0)
Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects (2014) (0)
[Multicenter trials in the treatment of arterial hypertension. Socioeconomic repercussions]. (1984) (0)
Patient Compliance in Hypertension Care: The Critical Role of the Computer (1982) (0)
[Urinary excretion of antidiuretic hormone in normal man: search for the natremic and osmolar thresholds of A.D.H. liberation]. (1974) (0)
[Kallikrein secretion by the isolated perfused rat kidney. Role of perfusion pressure and the renin-angiotensin system]. (1985) (0)
Response to Letter to Regarding Article, “Effects of Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial” (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Joël Ménard?

Joël Ménard is affiliated with the following schools: